Phase 1 trial demonstrates encouraging clinical activity of investigational immunotherapy for relapsed or refractory multiple myelomaNovel investigational dual-antigen-targeting immunotherapy binds to B-cell maturation antigen (BCMA) and GPRC5D on myeloma cells, as well as CD3 on T-cells CHICAGO, June 3, 2025 /PRNewswire/ -- Johnson & Johnson announced today initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients with relapsed or refractory multipl ...

Results from the Phase 3 AMPLITUDE study show the potential of niraparib and abiraterone acetate to delay cancer progression and worsening of symptoms1 Data show a nearly 50 percent reduction in disease progression in BRCA-altered mHSPC1 BEERSE, BELGIUM, June 03, 2025 (GLOBE NEWSWIRE) -- Johnson & Johnson announced today first results from the Phase 3, randomised, double-blind, placebo-controlled AMPLITUDE study evaluating the combination of niraparib and abiraterone acetate plus prednisone (AAP) in patien ...

CHONGQING, CHINA - APRIL 20: In this photo illustration, the Merck logo is displayed on a smartphone ... More screen, with the company's green-themed branding visible in the background, on April 20, 2025, in Chongqing, China. (Photo by Cheng Xin/Getty Images)Getty ImagesWhy would you consider buying Johnson & Johnson stock (NYSE:JNJ) at 17 times its trailing earnings when Merck stock (NYSE: MRK) trades at around 13 times? After all, Merck has nearly 10% average revenue growth compared to J&J’s modest 4%, an ...

Results from the Phase 3 AMPLITUDE study show the potential of AKEEGA® (niraparib and abiraterone acetate dual-action tablet) to delay cancer progression and worsening of symptomsData show a nearly 50 percent reduction in disease progression in BRCA-altered mCSPC vs. current standard of careCHICAGO, June 3, 2025 /PRNewswire/ -- Johnson & Johnson announced today first results from the Phase 3, randomized, double-blind, placebo-controlled AMPLITUDE study evaluating the combination of niraparib and abiraterone ...

When I think "iconic company, boring stock," Johnson & Johnson ( JNJ ) comes to mind immediately. But boring can be great, especially in chaotic stock market periods. Since I declared myself ready to "say yesI'm Rob Isbitts, founder of Sungarden Investment Publishing. I run the new investing group Sungarden Investors Club, a community dedicated to navigating the modern investment climate with humility, discipline, and a non-traditional approach to income investing. I've been charting investments since the 1 ...

Some of the best dividend stocks in the world are on sale right now. Shares of Federal Realty Investment Trust (FRT -0.30%), Johnson & Johnson (JNJ -0.56%), and PepsiCo (PEP -0.56%) are currently down 8% to 27% from their 52-week highs. Those sell-offs have pushed their dividend yields even higher. With elite records of dividend growth -- each has delivered more than 50 years of consecutive annual payment increases -- they are very attractive investment opportunities right now. An elite REITShares of Federa ...

Johnson & Johnson (NYSE:JNJ) Bernstein’s 41st Annual Strategic Decisions Conference Call May 28, 2025 9:00 AM ET Company Participants Joaquin Duato - Chairman and Chief Executive Officer Joseph Wolk - Executive Vice President, Chief Financial Officer Conference Call Participants Lee Hambright - Bernstein Lee Hambright All right, thank you, everybody. Thanks, guys. I'm Lee Hambright, US MedTech Analyst at Bernstein, and we are thrilled to host Johnson & Johnson. We have Chairman and CEO, Joaquin Duato and CF ...

Johnson & Johnson (JNJ) FY 2025 Conference May 28, 2025 09:00 AM ET Speaker0 Alright. Thank you, everybody. Thanks, guys. I'm Lee Hambrite, US med tech analyst at Bernstein, and we are thrilled to host Johnson and Johnson. We have chairman and CEO, Joaquin Guato, and CFO, Joe Wall. Guys, for being here. Speaker1 Thank you. Thanks for having us. Speaker0 So we're scheduled for a fifty minute fireside chat. Just a reminder that investors can submit questions at any time through Pigeonhole, and we'll try to wo ...

I am focused on growth and dividend income. My personal strategy revolves around setting myself up for an easy retirement by creating a portfolio which focuses on compounding dividend income and growth. Dividends are an intricate part of my strategy as I have structured my portfolio to have monthly dividend income which grows through dividend reinvestment and yearly increases. Feel free to reach out to me on Seeking AlphaAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any ...

The latest trading session saw Johnson & Johnson (JNJ) ending at $152.51, denoting a -0.44% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily loss of 0.04%.The the stock of world's biggest maker of health care products has fallen by 1.42% in the past month, lagging the Medical sector's gain of 1.44% and the S&P 500's gain of 13.42%.Market participants will be closely following the financial results of Johnson & Johnson in its upcoming release. In that report, anal ...